These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
在Biogen-Eisai出人意料地贏得阿爾茨海默氏症試驗後,這些股票備受關注
One of the most-watched Alzheimer's therapies in the clinic, Biogen Inc (NASDAQ:BIIB)-Eisai Limited's (OTC:ESALY) experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months in early Alzheimer's. In July 2022, the FDA accepted the marketing application for lecanemab under the accelerated approval pathway and granted a Priority Review. The PDUFA date is Jan. 6, 2023. Also Read: This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval. Several stocks related to Alzheimer's programs are gaining. SVB Leerink said these positive results would reinvigorate the Alzheimer's...
One of the most-watched Alzheimer's therapies in the clinic, Biogen Inc (NASDAQ:BIIB)-Eisai Limited's (OTC:ESALY) experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months in early Alzheimer's.
In July 2022, the FDA accepted the marketing application for lecanemab under the accelerated approval pathway and granted a Priority Review. The PDUFA date is Jan. 6, 2023.
Also Read: This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval.
Several stocks related to Alzheimer's programs are gaining. SVB Leerink said these positive results would reinvigorate the Alzheimer's...
這是診所裏最受關注的阿爾茨海默氏症療法之一 百健公司 (納斯達克股票代碼:BIIB)-衛材有限公司 (OTC: ESALY)與阿爾茨海默氏症早期18個月的安慰劑相比,實驗性lecanemab的臨床衰退...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!